Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., LTD.

Product Overview

Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets belong to the antidiabetic therapeutic class and are a fixed-dose combination of an SGLT2 inhibitor and biguanide. Dapagliflozin lowers blood glucose via urinary glucose excretion, while metformin hydrochloride (extended-release) reduces hepatic glucose production and improves peripheral insulin sensitivity. The extended-release design delivers sustained metformin exposure, combining two complementary mechanisms for synergistic glycemic control.

Indications

This formulation is indicated for the treatment of type 2 diabetes mellitus in adult patients to improve glycemic control, when dapagliflozin and metformin are appropriate.

Specifications & Packaging

Specifications: 5 mg/1000 mg, 10 mg/1000 mg

Packaging: Aluminium-Aluminium blister pack, 7 tablets / blister， 4 blisters / box

Quality & Supply Advantage

Manufactured in full GMP compliance, the tablets conform to international quality standards, with stringent control over impurities, dissolution and stability. We guarantee stable supply, competitive pricing, end-to-end quality control and flexible technical support to facilitate your registration and formulation development.

Product Highlights

This fixed-dose extended-release combination integrates two complementary antihyperglycemic mechanisms. It simplifies medication regimen, reduces pill burden, and provides sustained glycemic control. It addresses clinical needs for combined therapy in patients with type 2 diabetes mellitus.

Collaboration Options

We are able to supply qualified finished dosage forms, offer technology transfer and other flexible cooperation models. We welcome your enquiries for further information and potential collaboration.